- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: example 90 [US20160264548]
Compound class: Synthetic organic
Comment: This compound is reported as an irreversible, covalent inhibitor of Bruton's tyrosine kinase (BTK) . It is compound 23 (example 90) as claimed in Merck's patent US20160264548A1 .
Because of its expression pattern on B cells, macrophages, neutrophils, and monocytes (NOT T cells) and its essential role in B lymphocyte development and function, BTK continues to be investigated as a valid therapeutic target for the treatment of diseases that involve B-cell and/or macrophage activation (e.g. B-cell malignancies, asthma and rheumatoid arthritis). Ibrutinib was the first-in-class small molecule BTK inhibitor to reach the clinic. Unfortunately, ibrutinib causes severe adverse effects that are in the main, attributed to its off-target profile. As a result, second-generation BTK inhibitors with optimised structures and improved selectivity are being developed. Inhibitor 16 described here, exhibits comparable cellular potency to ibrutinib but has a higher kinome selectivity against undesirable off-targets.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
1. Qiu H, Caldwell RD, Neagu C, Mochalkin I, Liu-Bujalski L, Jones R, Tate D, Johnson TL, Gardberg A. (2016)
Heteroaryl compounds as btk inhibitors and uses thereof.
Patent number: US20160264548A1. Assignee: Merck Patent GmbH. Priority date: 21/10/2013. Publication date: 15/09/2016.
2. Qiu H, Liu-Bujalski L, Caldwell RD, Follis AV, Gardberg A, Goutopoulos A, Grenningloh R, Head J, Johnson T, Jones R et al.. (2018)
Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit.
Bioorg Med Chem Lett, 28 (17): 2939-2944. [PMID:30122225]